New combo aims to deepen remission in early CML
NCT ID NCT05007873
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combination leads to deeper, longer-lasting responses without increasing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at tough childhood leukemia
- New drug combo shows promise for tough leukemia cases
- New drug combo aims to outsmart tough leukemia without chemo
- Massive trial seeks best chemo cocktail for kids with leukemia
- Your personality could be key to sticking with CML treatment
- New strategy aims to tame common virus after stem cell transplants